Literature DB >> 9603453

Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells.

S M Mariani1, P H Krammer.   

Abstract

Like other members of the TNF family, TRAIL/Apo-2 ligand induces apoptosis in sensitive target cells in a caspase-dependent fashion. We recently found that TRAIL may be constitutively expressed on the surface of mouse and human tumor cells of T and B origin. To define the pattern of TRAIL expression in normal immune cells, freshly isolated splenocytes, Concanavalin A/IL-2-activated T cells and lipopolysaccharide-activated B cells were analyzed by surface staining with or without secondary stimulation. Activated, but not resting, CD3+ cells expressed TRAIL in an activation-dependent fashion. Conversely, freshly isolated B220+ cells displayed surface TRAIL and CD95L that were retained following activation. Restimulation with the protein kinase C activator phorbol 12-myristate 13-acetate and the calcium ionophore ionomycin or an agonistic anti-CD3 monoclonal antibody induced significant up-regulation of surface TRAIL and CD95L in CD3+, TCRalphabeta cells with CD4+ or CD8+ phenotype. Similarly to CD95L, TRAIL up-regulation was protein synthesis dependent and cyclosporin A sensitive. These results indicate that both TRAIL and CD95L are displayed on the cell surface of activated immune cells and may thus represent complementary effector pathways in the regulatory functions of T and B cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603453     DOI: 10.1002/(SICI)1521-4141(199805)28:05<1492::AID-IMMU1492>3.0.CO;2-X

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  47 in total

Review 1.  Death and destruction of activated T lymphocytes.

Authors:  I N Crispe
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

Review 2.  TRAIL, Bim, and thymic-negative selection.

Authors:  Shi-Jun Zheng; Youhai H Chen
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  Recombinant adenoviruses expressing TRAIL demonstrate antitumor effects on non-small cell lung cancer (NSCLC).

Authors:  F Yang; P Shi; X Xi; S Yi; H Li; Q Sun; M Sun
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

4.  Fas-associated protein with death domain (FADD)-independent recruitment of c-FLIPL to death receptor 5.

Authors:  Tai-Guang Jin; Alexei Kurakin; Nordine Benhaga; Karon Abe; Mehrdad Mohseni; Ferry Sandra; Keli Song; Brian K Kay; Roya Khosravi-Far
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

Review 5.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

6.  Alveolar epithelial cells in idiopathic pulmonary fibrosis display upregulation of TRAIL, DR4 and DR5 expression with simultaneous preferential over-expression of pro-apoptotic marker p53.

Authors:  Khondoker M Akram; Nicola J Lomas; Nicholas R Forsyth; Monica A Spiteri
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  A critical role for TRAIL in resolution of granulomatous experimental autoimmune thyroiditis.

Authors:  Y Fang; G C Sharp; H Yagita; H Braley-Mullen
Journal:  J Pathol       Date:  2008-12       Impact factor: 7.996

8.  A critical role of TRAIL expressed on cotransplanted hepatic stellate cells in prevention of islet allograft rejection.

Authors:  Horng-Ren Yang; Ching-Chuan Hsieh; Lianfu Wang; John J Fung; Lina Lu; Shiguang Qian
Journal:  Microsurgery       Date:  2010-05       Impact factor: 2.425

Review 9.  The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Authors:  Nathan Cummins; Andrew Badley
Journal:  Curr Mol Med       Date:  2009-05       Impact factor: 2.222

Review 10.  Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in central nervous system inflammation.

Authors:  Olaf Hoffmann; Frauke Zipp; Joerg R Weber
Journal:  J Mol Med (Berl)       Date:  2009-05-17       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.